Renal Artery Stenosis in a Patient with Flash Pulmonary Edema
A 74-year-old man with long-standing hypertension and chronic kidney disease (baseline creatinine 2.1 mg/dL, eGFR 32) presents with recurrent flash pulmonary edema - three admissions in 6 months, each with preserved ejection fraction (EF 60%) and bilateral renal artery stenosis on prior imaging (right 80%, left 60%). He is on maximal medical therapy including a diuretic, ACE inhibitor (tolerated), statin, and beta-blocker. Medical management has not prevented recurrences. Nephrology is reluctant to endorse intervention; cardiology wants a stent. The patient is frustrated and asks whether stenting will "fix the kidneys."
1. What is the evidence-based role of renal artery stenting in this patient, and how do you frame the decision?
Read the worked answer
Large randomized trials of renal artery stenting for atherosclerotic renal artery stenosis (e.g., ASTRAL and CORAL) showed no meaningful benefit over medical therapy for blood pressure control, renal function preservation, or cardiovascular events in broadly selected populations. So the default answer to "will stenting fix the kidneys?" is no - stenting is not proven to improve renal outcomes in unselected atherosclerotic disease.
However, the trials largely excluded or underrepresented specific high-risk phenotypes, and the recognized exception is flash pulmonary edema / recurrent heart failure with preserved EF attributable to bilateral severe stenosis or stenosis in a solitary functioning kidney. This patient fits that phenotype: recurrent flash pulmonary edema, preserved EF, bilateral disease with a dominant right lesion.
Framing: the indication is not "fix the kidneys" but "prevent recurrent pulmonary edema" in a carefully selected patient who has failed maximal medical therapy. This is a judgement call - the exam wants you to recognize the trial data, then recognize the narrow exception rather than applying either extreme reflexively.
2. What pre-procedural and peri-procedural considerations matter given his CKD and bilateral disease?
Read the worked answer
Several concrete risks:
- Contrast-associated AKI - eGFR 32 means he is at risk. Use minimal low-osmolar (or iso-osmolar) contrast, hydration, and possibly a carbon dioxide angiogram or intravascular ultrasound to reduce contrast load. Avoid nephrotoxins.
- Bilateral disease / solitary-functioning-kidney physiology - stenting one side while the other is compromised can precipitate acute renal failure if there is any complication (dissection, occlusion, atheroembolism). Plan which side to treat (usually the dominant/right 80% lesion) and have a strategy if the result is suboptimal.
- Atheroembolism - catheter manipulation in a diffusely atherosclerotic aorta can cause cholesterol emboli, which can worsen renal function irreversibly; use careful technique and avoid excessive wire/catheter trauma.
- Medication management - antiplatelet therapy for the stent, blood pressure control, and coordination with nephrology and cardiology about diuretics and ACE inhibitor timing.
- Informed consent - the patient should understand that the goal is symptom control (pulmonary edema), that renal function may not improve and could worsen, and that the evidence base is a selected-population exception, not a general rule.